New Agents for the Treatment of Acute Lymphoblastic Leukemia

New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic....

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Saha, Vaskar (Editor ), Kearns, Pamela (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York, NY : Springer New York : Imprint: Springer, 2011.
Edición:1st ed. 2011.
Temas:
Cancer.
Pharmacology.
Cancer Biology.
Acceso en línea:Texto Completo
Tabla de Contenidos:
  • The need for new agents
  • Identifying pre-clinical agents
  • Pre-clinical evaluation
  • Design of early phase trials
  • Strategies for trial design and analyses
  • Overview on Molecular and Animal models of ALL
  • Apoptosis, BCL2
  • Targeting Stem Cells
  • Nucleoside Analogues
  • Flt3 Inhibitors
  • Tyrosine Kinase Inhibitors
  • Monoclonal Antibodies
  • Proteasome inhibitors
  • Targeting epigenetic pathways in ALL.- Incorporating new therapies in frontline protocols.-.

Ejemplares similares